Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAmélie FontaineAPAnthea Peters

Discussion

Loading...

Member takes

Overview

Population-based study reveals similar selection frequencies for fixed-duration and continuous therapies in CLL, highlighting factors influencing treatment choice.

Key Points

  • To determine the real-world distribution of first-line treatment strategies for chronic lymphocytic leukemia/small lymphocytic lymphoma and identify influencing factors.
  • Retrospective, population-based study
  • Included treatment-naïve patients initiating first-line therapy for CLL/SLL in Alberta, Canada
  • Statistical comparisons performed using Fisher's exact test
  • 75 patients (51%) selected targeted fixed-duration therapies, including venetoclax-obinutuzumab
  • 65 patients (44%) received continuous BTK inhibitors
  • Factors influencing therapy selection included age, presence of TP53 mutations, and patient preferences

Cite This Study

Fontaine et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4d0https://doi.org/10.1182/blood-2025-4513
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‐World Selection of Venetoclax‐Obinutuzumab Versus <scp>BTK</scp> Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma2026
  2. 2Real‑world effectiveness and patient-centered outcomes of fixed‑duration vs continuous first‑line therapy in chronic lymphocytic leukemia (CLL)2025
  3. 3An international view on the current approaches to frontline chronic lymphocytic leukemia therapy2025
  4. 4A genomic analysis of patients with chronic lymphocytic leukemia treated with fixed duration therapy in a first-line setting in alberta, Canada2025
  5. 5Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis2025